Geode Capital Management LLC Buys 31,612 Shares of AxoGen, Inc. (NASDAQ:AXGN)

Geode Capital Management LLC lifted its stake in AxoGen, Inc. (NASDAQ:AXGN) by 3.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,010,508 shares of the medical equipment provider’s stock after acquiring an additional 31,612 shares during the period. Geode Capital Management LLC owned 2.30% of AxoGen worth $14,170,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in AXGN. First Light Asset Management LLC raised its position in shares of AxoGen by 336.6% in the 2nd quarter. First Light Asset Management LLC now owns 3,344,033 shares of the medical equipment provider’s stock worth $24,211,000 after acquiring an additional 2,578,147 shares in the last quarter. Divisadero Street Capital Management LP increased its position in AxoGen by 587.2% during the 2nd quarter. Divisadero Street Capital Management LP now owns 686,994 shares of the medical equipment provider’s stock valued at $4,974,000 after buying an additional 587,024 shares in the last quarter. Parkman Healthcare Partners LLC acquired a new position in AxoGen during the 3rd quarter valued at about $5,789,000. FMR LLC increased its position in AxoGen by 743.1% during the 3rd quarter. FMR LLC now owns 178,957 shares of the medical equipment provider’s stock valued at $2,509,000 after buying an additional 157,730 shares in the last quarter. Finally, Eagle Asset Management Inc. acquired a new position in AxoGen during the 3rd quarter valued at about $1,728,000. 80.29% of the stock is owned by institutional investors.

AxoGen Trading Down 1.0 %

Shares of NASDAQ:AXGN opened at $16.49 on Tuesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47. The business’s 50-day moving average is $14.19 and its 200 day moving average is $12.11. The firm has a market capitalization of $725.69 million, a P/E ratio of -51.53 and a beta of 1.06. AxoGen, Inc. has a 1 year low of $5.55 and a 1 year high of $17.23.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised AxoGen from a “hold” rating to a “buy” rating in a research report on Tuesday, October 15th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, AxoGen has a consensus rating of “Buy” and an average target price of $15.00.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.